Gene therapy data whipsaws
BEAM is bouncing around violently after reporting 18-month clinical data for its AATD gene therapy BEAM-302, with the stock still down sharply on the day despite the moderate upward spike, suggesting traders are wrestling with whether the results represent genuine progress or more of the same disappointment flagged hours earlier.
Sources: https://www.invest
Previous verdicts for BEAM
- AI Search: Law Firm Investigation Adds Modest Overhang for BEAM — 2026-10-08
- ARK Buying Fuels BEAM Spike — 2026-09-22
- Safety jitters hit gene editing — 2026-09-10
- Gene therapy data whipsaws — 2026-09-09
- Gene therapy data disappoints — 2026-09-08
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works